fda import alert 66-80 glp-1 fda import alert 66-80 glp-1 FDA Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling-bsmoothhr Compounded Semaglutide & Tirzepatide 2025:

TSH (thyroid-stimulating hormone): Thyroid dysfunction is common in GLP-1 candidate populations and can significantly confound both weight response and metabolic improvement if left unaddressed

Some patients and clinicians have explored combining ketogenic diets with prescription GLP-1 receptor agonist therapy, though this approach requires careful medical supervision

Zepbound is approved by the FDA as a weight loss management treatment for people with obesity or those who are overweight with at least one weight-related condition such as high blood pressure

Whatever the case, uncovering these trends helps you pivot your routine accordingly

Emerging Trends Expanded Clinical Indications: GLP-1 receptor agonists were initially approved for type 2 diabetes in 2005, and their indications have expanded over time